Week In Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Lively discussions were fueled last week by policy developments, financial reports, and strategic expansions in the Cannabis and Psychedelics industries. From federal rescheduling debates to global market moves, the Highly Capitalized Network team delivers the most notable news straight from the industry frontlines.

1. Cannabis stocks climbed as President Donald Trump considered a potential shift to re(de)schedule Cannabis from Schedule I to Schedule III within weeks, a move that could finally reduce tax burdens and significantly expand research opportunities.
2. The Senate advocated for increased research on both Psychedelics and Cannabis despite Schedule I constraints, while NORML urged supporters and advocates to push for ultimate re(de)scheduling and conviction relief.
3. In New York City, near-school dispensaries avoided closures following regulatory disputes, underscoring state-level challenges.
4. Financial reports drew significant focus, with Q2 2025 earnings revealing a highly competitive market. Avant Brands reported $9.7 million in revenue, joined by other MSOs like Trulieve Cannabis Corp, Curaleaf, Verano Holdings, Jushi Holdings, Green Thumb Industries, MariMed, The Cannabist Co., Cresco Labs, Cronos Group, Ascend Wellness, TerrAscend, Village Farms, Grown Rogue, Planet 13, and Glass House Brands, all highlighting operational progress amid regulation, tax, and oversupply pressures. Aurora Cannabis and Canopy Growth shared Q1 FY2026 results, while Organigram reported Q3 FY2025 statements, reflecting varied fiscal cycles.
5. Cresco Labs strengthened its financial position with a $325 million senior secured term loan refinancing.
6. Strategic expansions also garnered attention. Curaleaf partnered with Miss Grass to broaden medical Cannabis access in Florida, while Snoop Dogg’s Death Row Cannabis entered Ohio’s market.
7. Canopy Growth and Aurora Cannabis, the latter launching its Whistler brand, expanded in Australia.
8. High Tide acquired a majority stake in Remexian Pharma GmbH to enter Germany’s medical Cannabis sector, where record Q2 2025 imports raised concerns about misuse.
9. Metrc and BioTrack partnered to advance compliance technology.
10. Michigan’s Cannabis market faces scrutiny over falling prices, raising stability concerns.
11. AYR Wellness exited Massachusetts in a financial restructuring, and the hemp beverage category’s long-term viability prompted debate.

In psychedelics, a study exploring psilocybin’s potential extraterrestrial origins sparked curiosity. Meanwhile, an international market report projected that the sector would reach $22.6 billion by 2033, driven by therapeutic advancements and investor interest.

HCN Insight

We note that federal rescheduling remains a pivotal catalyst for the Cannabis industry, promising tax relief and research opportunities. Financial reports reflect resilience and have been thoroughly analyzed by Viridian Capital Advisors. However, oversupply and taxation highlight the urgency of policy reform. Psychedelics, while less prominent, show strong growth potential, spurred by therapeutic innovation. These developments signal industries navigating bold opportunities alongside persistent regulatory and economic challenges.